Survival After Adrenalectomy for Metastatic Hepatocellular Carcinoma: A 25-year Institutional Experience.


Journal

World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052

Informations de publication

Date de publication:
Apr 2021
Historique:
accepted: 05 12 2020
pubmed: 24 12 2020
medline: 25 6 2021
entrez: 23 12 2020
Statut: ppublish

Résumé

Extrahepatic manifestation of hepatocellular carcinoma (HCC) is rare and primarily affects lung, lymph nodes and bone. Metastases to the adrenal glands are relatively infrequent. This 25-year institutional experience aimed for an analysis of factors influencing survival in patients undergoing surgery for HCC adrenal metastasis. A retrospective analysis of the institutional database of the Clinic for General-, Visceral- and Transplantation Surgery of the University Medical Center Mainz, Germany, was performed. Patients who underwent surgery for HCC adrenal metastases from January 1995 to June 2020 were included. Pre-, peri- and postoperative factors with potential influence on survival were assessed. In 16 patients (14 males, two females), one bilateral and 15 unilateral adrenalectomies were performed (13 metachronous, three synchronous). Thirteen operations were carried out via laparotomy, and three adrenalectomies were minimally invasive (two laparoscopic, one retroperitoneoscopic). Median overall survival (after HCC diagnosis) was 35 months, range: 5-198. Median post-resection survival (after adrenalectomy) was 15 months, range: 0-75. Overall survival was longer in patients with the primary HCC treatment being liver transplantation (median 66 months) or liver resection (median 51 months), compared to only palliative intended treatment of the primary with chemotherapy (median 35 months) or local ablation (median 23 months). Surgery is a feasible treatment option for patients with adrenal metastases originating from HCC. In patients who underwent adrenalectomy for HCC adrenal metastasis, overall survival was superior, if primary HCC treatment was potentially curative (liver transplantation or resection).

Sections du résumé

BACKGROUND BACKGROUND
Extrahepatic manifestation of hepatocellular carcinoma (HCC) is rare and primarily affects lung, lymph nodes and bone. Metastases to the adrenal glands are relatively infrequent. This 25-year institutional experience aimed for an analysis of factors influencing survival in patients undergoing surgery for HCC adrenal metastasis.
METHODS METHODS
A retrospective analysis of the institutional database of the Clinic for General-, Visceral- and Transplantation Surgery of the University Medical Center Mainz, Germany, was performed. Patients who underwent surgery for HCC adrenal metastases from January 1995 to June 2020 were included. Pre-, peri- and postoperative factors with potential influence on survival were assessed.
RESULTS RESULTS
In 16 patients (14 males, two females), one bilateral and 15 unilateral adrenalectomies were performed (13 metachronous, three synchronous). Thirteen operations were carried out via laparotomy, and three adrenalectomies were minimally invasive (two laparoscopic, one retroperitoneoscopic). Median overall survival (after HCC diagnosis) was 35 months, range: 5-198. Median post-resection survival (after adrenalectomy) was 15 months, range: 0-75. Overall survival was longer in patients with the primary HCC treatment being liver transplantation (median 66 months) or liver resection (median 51 months), compared to only palliative intended treatment of the primary with chemotherapy (median 35 months) or local ablation (median 23 months).
CONCLUSIONS CONCLUSIONS
Surgery is a feasible treatment option for patients with adrenal metastases originating from HCC. In patients who underwent adrenalectomy for HCC adrenal metastasis, overall survival was superior, if primary HCC treatment was potentially curative (liver transplantation or resection).

Identifiants

pubmed: 33354731
doi: 10.1007/s00268-020-05909-0
pii: 10.1007/s00268-020-05909-0
pmc: PMC7921034
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1118-1125

Références

Moreno P, de la Quintana Basarrate A, Musholt TJ et al (2013) Adrenalectomy for solid tumor metastases: results of a multicenter European study. Surgery 154:1215–1222
doi: 10.1016/j.surg.2013.06.021
Vazquez BJ, Richards ML, Lohse CM et al (2012) Adrenalectomy improves outcomes of selected patients with metastatic carcinoma. World J Surg 36:1400–1405. https://doi.org/10.1007/s00268-012-1506-3
doi: 10.1007/s00268-012-1506-3 pubmed: 22411083
Zeiger MA, Thompson GB, Duh QY et al (2009) The American association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract 15(Suppl 1):1–20
doi: 10.4158/EP.15.S1.1
Sancho JJ, Triponez F, Montet X et al (2012) Surgical management of adrenal metastases. Langenbeck’s Arch Surg 397:179–194
doi: 10.1007/s00423-011-0889-1
Lorenz K, Langer P, Niederle B et al (2019) Surgical therapy of adrenal tumors: guidelines from the German association of endocrine surgeons (CAEK). Langenbecks Arch Surg 404:385–401
doi: 10.1007/s00423-019-01768-z
Hornstein I, Schwarz C, Ebbing S et al (2015) Surgical resection of metastases to the adrenal gland: a single center experience. Langenbecks Arch Surg 400:333–339
doi: 10.1007/s00423-015-1293-z
Tsalis K, Zacharakis E, Sapidis N et al (2005) Adrenal metastasis as first presentation of hepatocellular carcinoma. World J Surg Oncol 3:50. https://doi.org/10.1186/1477-7819-3-50
doi: 10.1186/1477-7819-3-50 pubmed: 16042808 pmcid: 1187929
Sormaz IC, Yegen G, Akyuz F et al (2017) Recurrent hepatocellular carcinoma in the right adrenal gland 11 years after liver transplantation for hepatocellular carcinoma: a case report and literature review. Indian J Surg 79:450–454
doi: 10.1007/s12262-017-1680-5
Igarashi T, Harimoto N, Matsumura N et al (2019) Fairly rare small-diameter hepatocellular carcinoma with right adrenal gland metastasis having an inferior vena cava tumor thrombus: a case report. Surg Case Rep 5:170
doi: 10.1186/s40792-019-0705-7
Schlageter M, Quagliata L, Matter M et al (2016) Clinicopathological features and metastatic pattern of hepatocellular carcinoma: an autopsy study of 398 patients. Pathobiology 83:301–307
doi: 10.1159/000446245
Park JS, Yoon DS, Kim KS et al (2007) What is the best treatment modality for adrenal metastasis from hepatocellular carcinoma? J Surg Oncol 96:32–36
doi: 10.1002/jso.20773
Kanda M, Tateishi R, Yoshida H et al (2008) Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int 28:1256–1263
doi: 10.1111/j.1478-3231.2008.01864.x
Uchino K, Tateishi R, Shiina S et al (2011) Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 117:4475–4483
doi: 10.1002/cncr.25960
Aino H, Sumie S, Niizeki T et al (2014) Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis. Mol Clin Oncol 2:393–398
doi: 10.3892/mco.2014.259
Teegen EM, Mogl MT, Pratschke J et al (2018) adrenal metastasis of hepatocellular carcinoma in patients following liver resection or liver transplantation: experience from a tertiary referral center. Int J Surg Oncol 2018:4195076
pubmed: 30151282 pmcid: 6087597
Natsuizaka M, Omura T, Akaike T et al (2005) Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 20:1781–1787
doi: 10.1111/j.1440-1746.2005.03919.x
Hwang S, Moon DB, Ahn CS et al (2013) Risk-based long-term screening for hepatocellular carcinoma recurrence after living donor liver transplantation. Transpl Proc 45:3076–3084
doi: 10.1016/j.transproceed.2013.08.068
Chua TC, Morris DL (2012) Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surg Oncol 21:95–101
doi: 10.1016/j.suronc.2011.01.005
Jung J, Yoon SM, Park HC et al (2016) Radiotherapy for adrenal metastasis from hepatocellular carcinoma: a multi-institutional retrospective study (KROG 13–05). PLoS One 11:e0152642
doi: 10.1371/journal.pone.0152642
Huang J, Xie X, Lin J et al (2019) Percutaneous radiofrequency ablation of adrenal metastases from hepatocellular carcinoma: a single-center experience. Cancer Imaging 19:44
doi: 10.1186/s40644-019-0231-7
Uka K, Aikata H, Takaki S et al (2007) Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 13:414–420
doi: 10.3748/wjg.v13.i3.414
Yamakado K, Anai H, Takaki H et al (2009) Adrenal metastasis from hepatocellular carcinoma: radiofrequency ablation combined with adrenal arterial chemoembolization in six patients. AJR Am J Roentgenol 192:W300-305
doi: 10.2214/AJR.08.1752
Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34
doi: 10.1016/S1470-2045(08)70285-7
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in Advanced Hepatocellular Carcinoma. New Engl J Med 359:378–390
doi: 10.1056/NEJMoa0708857
Choi SB, Kim H, Kim SH et al (2011) Solitary extrahepatic intraabdominal metastasis from hepatocellular carcinoma after liver transplantation. Yonsei Med J 52:199–203
doi: 10.3349/ymj.2011.52.1.199
Bradley CT, Strong VE (2014) Surgical management of adrenal metastases. J Surg Oncol 109:31–35
doi: 10.1002/jso.23461
Strong VE, D’Angelica M, Tang L et al (2007) Laparoscopic adrenalectomy for isolated adrenal metastasis. Ann Surg Oncol 14:3392–3400
doi: 10.1245/s10434-007-9520-7
Kitaoka F, Yanaga K, Okudaira S et al (2005) Successful left adrenalectomy for metastatic hepatocellular carcinoma using hand-assisted laparoscopic surgery: report of a case. Surg Today 35:172–174
doi: 10.1007/s00595-004-2891-5
Takeda M, Yokoyama S, Hashimoto Y et al (2014) Two cases of resectable adrenal metastases from hepatocellular carcinoma. Gan To Kagaku Ryoho 41:2092–2094
pubmed: 25731433
Ha TY, Hwang S, Ahn CS et al (2014) Resection of metachronous adrenal metastasis after liver resection and transplantation for hepatocellular carcinoma. Dig Surg 31:428–435
doi: 10.1159/000370078
Momoi H, Shimahara Y, Terajima H et al (2002) Management of adrenal metastasis from hepatocellular carcinoma. Surg Today 32:1035–1041
doi: 10.1007/s005950200210

Auteurs

J I Staubitz (JI)

Section of Endocrine Surgery, Department of General, Visceral and Transplantation Surgery, University Medical Center, Johannes Gutenberg-University Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.

M Hoppe-Lotichius (M)

Department of General, Visceral and Transplantation Surgery, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.

J Baumgart (J)

Department of General, Visceral and Transplantation Surgery, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.

J Mittler (J)

Department of General, Visceral and Transplantation Surgery, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.

H Lang (H)

Department of General, Visceral and Transplantation Surgery, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.

T J Musholt (TJ)

Section of Endocrine Surgery, Department of General, Visceral and Transplantation Surgery, University Medical Center, Johannes Gutenberg-University Mainz, Langenbeckstraße 1, 55131, Mainz, Germany. musholt@uni-mainz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH